Cargando…

Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes

INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yu-Wei, Wang, Jun-Sing, Sheu, Wayne H-H, Lin, Shih-Yi, Lee, I-Te, Song, Yuh-Min, Fu, Chia-Po, Lee, Chia-Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300176/ https://www.ncbi.nlm.nih.gov/pubmed/28182722 http://dx.doi.org/10.1371/journal.pone.0171753

Ejemplares similares

Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV
por: Huang, Po-Kai, et al.
Publicado: (2019)

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
por: Liao, Wen-Ling, et al.
Publicado: (2017)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
por: Iwasaki, Masahiro, et al.
Publicado: (2012)

Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients: A retrospective observational study
por: Chen, Chin-Lan, et al.
Publicado: (2017)

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Glycated hemoglobin variability and retinopathy progression in type 1 diabetes: Is month‐to‐moth instability a better predictor?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Relationship between body weight and the increment in serum brain-derived neurotrophic factor after oral glucose challenge in men with obesity and metabolic syndrome: A prospective study
por: Lee, I-Te, et al.
Publicado: (2016)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin, Yi-Hsin, et al.
Publicado: (2019)

The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
por: Hsu, Wan-Chia, et al.
Publicado: (2022)

Genetic variants of dipeptidyl peptidase IV are linked to the clinicopathologic development of prostate cancer
por: Wen, Yu‐Ching, et al.
Publicado: (2023)

Dipeptidyl Peptidase 4 Stimulation Induces Adipogenesis-Related Gene Expression of Adipose Stromal Cells
por: Lai, Hsiao-Chi, et al.
Publicado: (2023)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo
por: Lin, Shian-Ren, et al.
Publicado: (2019)

Two-hour post-challenge hyperglycemia, but not fasting plasma glucose, associated with severity of coronary artery disease in patients with angina
por: Fu, Chia-Po, et al.
Publicado: (2018)

Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4
por: Huang, Po-Kai, et al.
Publicado: (2019)

The value of glycated hemoglobin as predictor of organ dysfunction in patients with sepsis
por: Lee, Young Seok, et al.
Publicado: (2019)

The synergistic effect of inflammation and metabolic syndrome on intraocular pressure: A cross-sectional study
por: Lee, I-Te, et al.
Publicado: (2017)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
por: Chen, Hsin-Hung, et al.
Publicado: (2019)

The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes
por: Lee, Chia-Lin, et al.
Publicado: (2020)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
por: Wang, Shen-Chih, et al.
Publicado: (2022)

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19
por: Chen, Chun-Fan, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Predictors of Glycated Hemoglobin among Jordanian Diabetic Patients
por: HAMMAD, Sawsan, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals
por: Hu, Di-Shuang, et al.
Publicado: (2019)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

Neuronal Roles of the Multifunctional Protein Dipeptidyl Peptidase-like 6 (DPP6)
por: Malloy, Cole, et al.
Publicado: (2022)

Encapsulation of 16-Hydroxycleroda-3,13-Dine-16,15-Olide in Mesoporous Silica Nanoparticles as a Natural Dipeptidyl Peptidase-4 Inhibitor Potentiated Hypoglycemia in Diabetic Mice
por: Huang, Po-Kai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n939rq0f1auf8scru6oeq1j25a